Stargardt Disease (STGD) Epidemiology Forecast 2025-2034

Stargardt disease (STGD) is the most prevalent childhood recessively inherited macular dystrophy. About 7% of all retinal degeneration is caused by STGD, which affects roughly 1 in 10,000 people. The illness typically first appears in early childhood or adolescence, though reports of a later onset have also been made.

Stargardt Disease (STGD) Epidemiology Forecast Report Coverage

The “Stargardt Disease (STGD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Stargardt disease (STGD). It projects the future incidence and prevalence rates of Stargardt disease (STGD) across various populations. The study covers age and type as major determinants of the Stargardt disease (STGD)-affected population. The report highlights patterns in the prevalence of Stargardt disease (STGD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Stargardt disease (STGD) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Stargardt Disease (STGD): Disease Overview

Stargardt disease (STGD) is a genetic eye condition that gradually impairs vision. It leads to degeneration in the macula, the central region of the retina that provides sharp and detailed vision. The most prevalent type of juvenile macular dystrophy is usually brought on by mutations in the ABCA4 gene, which causes a deposit of toxic lipofuscin in the retinal cells. Loss of central vision, trouble identifying faces, and poor color perception are among the symptoms, which typically manifest in childhood or adolescence. Although peripheral vision is usually unaffected, the disease gradually gets worse and has a major impact on day-to-day activities.

Stargardt Disease (STGD): Treatment Overview

Although there is no cure for Stargardt disease (STGD), management techniques aim to preserve residual vision and slow the disease's progression. It is recommended that patients wear sunglasses to prevent excessive exposure to ultraviolet (UV) rays and bright light. Novel therapies are being investigated to address the underlying genetic mutations and reduce the accumulation of toxic lipofuscin in retinal cells. Gene therapy, stem cell therapy, and other pharmacological methods are also used in the treatment of the disease. Adaptive technologies, lifestyle changes, and low-vision aids all assist people in adjusting to vision loss. Several clinical trials are being conducted to create possible treatments that could slow or stop the progression of the disease.

Epidemiology

The Stargardt disease (STGD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Stargardt disease (STGD) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Stargardt disease (STGD) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• A study revealed that in a total of 1,934 patients Stargardt disease-diagnosed patients, male patients made up the majority (63.14%). With 626 patients (31.87%), the second decade of life was the most common age group at presentation. Patients with higher socioeconomic status (0.077%), along with those who belonged to urban areas (0.079%), and students (0.17%) had higher overall prevalences.
• Although Stargardt disease (STGD) can strike at any age, it usually first manifests between the ages of 10 and 20. Patients are typically in their late 20s. For children, the median age of onset is approximately 8.5 years. For adults, the median age of onset is approximately 28.3 years.
• A genetic analysis of 28 patients with a Stargardt-like phenotype found that 75% of the patients were affected by the disease due to ABCA4 gene mutations. The genetic heterogeneity was indicated by the remaining 18% of patients who lacked any ABCA4 mutations.

Country-wise Stargardt Disease (STGD) Epidemiology

The Stargardt disease (STGD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Stargardt disease (STGD) varies significantly between countries due to differences in factors such as excessive exposure to bright light, vitamin A metabolism, and being a genetic disorder, among others. Despite being the most frequent cause of juvenile macular dystrophy, Stargardt disease is thought to affect 10 to 12.5 out of every 100,000 people in the United States. Additionally, the yearly incidence of this condition in the United Kingdom was estimated to be between 0.110 and 0.128 per 100,000 people.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, and treatment options of Stargardt disease (STGD) based on several factors.
• Stargardt disease (STGD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Stargardt disease (STGD)s are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Stargardt disease (STGD) epidemiology in the 8 major markets?
• What will be the total number of patients with Stargardt disease (STGD) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Stargardt disease (STGD) in the 8 major markets in the historical period?
• Which country will have the highest number of Stargardt disease (STGD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Stargardt disease (STGD) during the forecast period of 2025-2034?
• What are the currently available treatments for Stargardt disease (STGD)s?
• What are the disease risks, signs, symptoms, and unmet needs of Stargardt disease (STGD)?

This product will be delivered within 3-5 business days.